| Malignant neoplasm of ovary
Avastin vs Cytalux
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of ovary.Deep comparison between: Avastin vs Cytalux with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCytalux has a higher rate of injection site reactions vs Avastin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cytalux but not Avastin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Avastin
Cytalux
At A Glance
IV infusion
Every 2-3 weeks
VEGF inhibitor
IV infusion
Single pre-surgical dose
Folate receptor-targeted imaging agent
Indications
- Metastasis from malignant neoplasm of colon and/or rectum
- Non-Small Cell Lung Carcinoma
- Glioblastoma
- Renal Cell Carcinoma
- Cervix carcinoma
- Malignant neoplasm of ovary
- Fallopian Tube Carcinoma
- Primary Peritoneal Cancer
- Liver carcinoma
- Malignant neoplasm of ovary
- Malignant neoplasm of lung
Dosing
Metastasis from malignant neoplasm of colon and/or rectum 5 mg/kg IV every 2 weeks with bolus-IFL, or 10 mg/kg IV every 2 weeks with FOLFOX4; for 2nd-line after a bevacizumab product-containing regimen: 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy.
Non-Small Cell Lung Carcinoma 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel.
Glioblastoma 10 mg/kg IV every 2 weeks.
Renal Cell Carcinoma 10 mg/kg IV every 2 weeks with interferon alfa.
Cervix carcinoma 15 mg/kg IV every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan.
Malignant neoplasm of ovary, Fallopian Tube Carcinoma, Primary Peritoneal Cancer Stage III/IV following initial surgical resection: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, then 15 mg/kg every 3 weeks as single agent for up to 22 total cycles. Platinum-resistant recurrent: 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan. Platinum-sensitive recurrent: 15 mg/kg every 3 weeks with carboplatin and paclitaxel or carboplatin and gemcitabine for 6-10 cycles, then 15 mg/kg every 3 weeks as single agent.
Liver carcinoma 15 mg/kg IV every 3 weeks administered after atezolizumab 1,200 mg IV on the same day.
Malignant neoplasm of ovary 0.025 mg/kg single IV infusion diluted in 250 mL 5% Dextrose Injection, administered over 60 minutes via dedicated infusion line, 1 to 9 hours prior to surgery.
Malignant neoplasm of lung 0.025 mg/kg single IV infusion diluted in 250 mL 5% Dextrose Injection, administered over 60 minutes via dedicated infusion line, 1 to 24 hours prior to surgery.
Contraindications
—
—
Adverse Reactions
Most common (>10%) Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis.
Serious Gastrointestinal perforations and fistulae, wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome, renal injury and proteinuria, infusion-related reactions, ovarian failure, congestive heart failure.
Postmarketing Polyserositis, pulmonary hypertension, mesenteric venous occlusion, gastrointestinal ulcer, intestinal necrosis, anastomotic ulceration, pancytopenia, gallbladder perforation, osteonecrosis of the jaw, renal thrombotic microangiopathy, nasal septum perforation, arterial aneurysms, dissections, and rupture.
Most common (>=1%) Nausea, vomiting, abdominal pain, flushing, other infusion-related reactions, hypersensitivity, elevation in blood pressure, dyspepsia, chest discomfort
Pharmacology
Bevacizumab is a VEGF inhibitor that binds VEGF and prevents its interaction with receptors Flt-1 and KDR on endothelial cells, inhibiting endothelial cell proliferation and new blood vessel formation, thereby reducing tumor microvascular growth and metastatic disease progression.
Pafolacianine binds to alpha and beta folate receptors on cells, is internalized via receptor-mediated endocytosis, and accumulates intracellularly, enhancing lesion visualization through the differential level of expression and accessibility of folate receptors within lesions relative to normal tissue.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Avastin
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
No coverage data available for Cytalux.
UnitedHealthcare
Avastin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
No coverage data available for Cytalux.
Humana
Avastin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
No coverage data available for Cytalux.
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Avastin.
No savings programs available for Cytalux.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AvastinView full Avastin profile
CytaluxView full Cytalux profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.